"Without controls in place as reliable as the set of immune receptor templates we have developed to eliminate any PCR bias, standardization of a kit would be quite difficult," explained Adaptive co-founder Dr. Harlan Robins.Adaptive has several other assays being prepped for clinical use in oncology/hematology, immunology, and infectious diseases.
Adaptive Biotechnologies Launches ClonoSEQ, A More Sensitive, Accurate Assay To Detect Minimal Residual Disease (MRD) In Blood-based Cancers.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.